Excel Therapeutics to Launch Four New Culture Media Products This Year
"Targeting the Immunotherapy Market"
Expanding Culture Media Portfolio to T Cells, NK Cells, and Exosomes
Two AOF-Based Products Launched; Securing Chinese Clients and Distributors
Excel Therapeutics, a company specializing in cell and gene therapy (CGT) culture media, announced on September 15 that it will sequentially launch four new media products within the year.
The products Excel Therapeutics is preparing to release are ▲CellCor™ EXO CD AOF ▲CellCor™ T CD AOF ▲CellCor™ NK XF ▲CellCor™ MSC CD AOF. According to the company, all four products have completed process development and are currently undergoing technology transfer to the production division.
CellCor™ EXO CD AOF and CellCor™ T CD AOF are based on chemically defined medium (CD) and xeno-free medium (XF), and incorporate the ‘AOF’ (Animal-Origin Free) technology that excludes animal-derived components. By eliminating both animal- and human-derived ingredients, these products offer improved raw material safety and consistency in the culture environment.
The EXO CD AOF product has signed Chinese company Xiangya Bio as a major customer and distributor, while T CD AOF has secured Bluemage Biotechnology as a key customer and distributor. Through the launch of its new products, Excel Therapeutics plans to expand its supply in international markets, including China.
CellCor™ NK XF is a dedicated medium developed to enable NK cell proliferation without the need for feeder cells. The company is currently in discussions to supply this product to new clients overseas, including those in China, and expects to broaden its customer base in the NK cell therapy sector.
The company's flagship product line MSC CD AOF will be expanded to include a version without phenol red, called ‘MSC CD AOF’. The intent is to diversify the product range so that various culture conditions can be accommodated during the cell therapy production process.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Haemin Jeong, Head of Research at Excel Therapeutics, stated, “These four new products have been developed based on demand from global clients and through technical validation. We will expand our application areas to immunotherapy products, such as T cell and NK cell therapies, and secure new customers and markets.”
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.
